Lancet PsychiatryPub Date : 2026-11-11DOI: 10.1016/S2215-0366(26)00328-7
Sem Cohen, Edoardo Ostinelli, Akihiro Takamiya, Bram Storosum, Alexander Verweij, Joost Daams, Taina Mattila, Anthonius de Boer, Daniel Geller, Stefan Leucht, Dan Stein, Jasper Zantvoord, Andrea Cipriani, Damiaan Denys
{"title":"Comparative efficacy and tolerability of pharmacological interventions for the acute treatment of obsessive-compulsive disorder across the lifespan: a systematic review and network meta-analysis.","authors":"Sem Cohen, Edoardo Ostinelli, Akihiro Takamiya, Bram Storosum, Alexander Verweij, Joost Daams, Taina Mattila, Anthonius de Boer, Daniel Geller, Stefan Leucht, Dan Stein, Jasper Zantvoord, Andrea Cipriani, Damiaan Denys","doi":"10.1016/S2215-0366(26)00328-7","DOIUrl":"https://doi.org/10.1016/S2215-0366(26)00328-7","url":null,"abstract":"<p><strong>Background: </strong>Pharmacological treatment is recommended for obsessive-compulsive disorder. Several options are available, yet little is known on comparative effects of individual medications. We aimed to elucidate the efficacy and tolerability of pharmacotherapy for people with obsessive-compulsive disorder, across the lifespan.</p><p><strong>Methods: </strong>We did a systematic review and network meta-analysis comparing short-term pharmacological interventions for obsessive-compulsive disorder. We searched multiple databases, including MEDLINE, Embase, PsycInfo, and the Cochrane Central Register of Controlled Trials, for literature on licensed or recommended pharmacological treatments for obsessive-compulsive disorder, without age restrictions, from database inception up to March 11, 2026. We included double-blind, randomised controlled trials with outcomes between 8 and 16 weeks. Two reviewers independently and in duplicate extracted outcomes, with a quality check done by a third reviewer. Primary outcomes were efficacy, defined as change from baseline score, and tolerability, defined as the proportion of participants discontinuing treatment due to adverse events. Separately for children and adolescents (aged 0-17 years) and adults (aged ≥18 years), we calculated standardised mean differences (SMDs) and odds ratios (ORs) with random-effects pairwise and network meta-analysis. The certainty of evidence was assessed using the Confidence in Network Meta-Analysis (CINeMA) framework. People with lived experience of obsessive-compulsive disorder were involved in the entire review process, including protocol development, writing, and interpretation of the findings. The study was preregistered in Open Science Framework (identifier 4V3GS).</p><p><strong>Findings: </strong>We included 52 randomised controlled trials with 7316 participants. Nine trials were included for children and adolescents (N=822; median age 12·5 years [IQR 11·6-13·2]; 352 [55%] male and 285 [45%] female among 637 participants with reported sex distribution). 43 trials were included for adults (N=6494; median age 36·4 years [35·0-37·9]; 3105 [49%] male and 3200 [51%] female among 6305 participants with reported sex distribution). Data on ethnicity were reported in 15 (29%) of 52 randomised controlled trials, using inconsistent definitions. In children and adolescents, clomipramine was more efficacious than placebo (SMD -1·19, 95% CI -1·73 to -0·64, CINeMA low), as were sertraline (-0·52, -0·80 to -0·02, low), fluoxetine (-0·43, -0·76 to -0·10, low), and fluvoxamine (-0·39, -0·71 to -0·07, low). Clomipramine was more efficacious than fluoxetine (SMD -0·75, 95% CI -1·39 to -0·11; very low), fluvoxamine (-0·79, -1·43 to -0·16; very low), paroxetine (-0·87, -1·51 to -0·22; very low), and sertraline (-0·87, -1·51 to -0·22; very low). Only sertraline was less tolerable than placebo (OR 4·51, 95% CI 1·36 to 14·96; low). In adults, clomipramine (SMD -0·71, 95% CI -0·88 to -","PeriodicalId":48784,"journal":{"name":"Lancet Psychiatry","volume":" ","pages":""},"PeriodicalIF":21.1,"publicationDate":"2026-11-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149395812","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Lancet PsychiatryPub Date : 2026-11-11DOI: 10.1016/S2215-0366(26)00329-9
Themistoklis Pantazakos, Gert-Jan Vanaken
{"title":"Psychotherapy for autistic adults lacks guidance on the conduct of therapy itself.","authors":"Themistoklis Pantazakos, Gert-Jan Vanaken","doi":"10.1016/S2215-0366(26)00329-9","DOIUrl":"https://doi.org/10.1016/S2215-0366(26)00329-9","url":null,"abstract":"","PeriodicalId":48784,"journal":{"name":"Lancet Psychiatry","volume":" ","pages":""},"PeriodicalIF":21.1,"publicationDate":"2026-11-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149395813","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Lancet PsychiatryPub Date : 2026-11-10DOI: 10.1016/S2215-0366(26)00330-5
Eleanor Longden, Alison Branitsky, Callum Glen, Verity Bell, Emmeline Joyce, Samantha E Bowe, Dirk Corstens, Rob Dudley, Amy Hardy, Bryony Sheaves, Richard Emsley, Melissa Pyle, Daniel Freeman, Wendy Jones, Anthony P Morrison
{"title":"Dialogical therapy plus treatment as usual versus treatment as usual in adults with distressing and persistent auditory hallucinations in the UK (Talking with Voices-II): a randomised controlled trial.","authors":"Eleanor Longden, Alison Branitsky, Callum Glen, Verity Bell, Emmeline Joyce, Samantha E Bowe, Dirk Corstens, Rob Dudley, Amy Hardy, Bryony Sheaves, Richard Emsley, Melissa Pyle, Daniel Freeman, Wendy Jones, Anthony P Morrison","doi":"10.1016/S2215-0366(26)00330-5","DOIUrl":"https://doi.org/10.1016/S2215-0366(26)00330-5","url":null,"abstract":"<p><strong>Background: </strong>Existing treatments for auditory hallucinations (hereafter voice hearing) among people with serious mental health problems (SMHPs; diagnoses include schizophrenia spectrum disorders, bipolar disorders, and personality disorders) show only modest clinical benefits, produce inconsistent long-term outcomes, and seldom prioritise personal recovery as a primary treatment goal. We aimed to investigate the effectiveness of Talking with Voices (TwV), a lived-experience informed intervention in which therapists engage in direct dialogue with voices, in improving both personal recovery and clinical outcomes for individuals experiencing persistent and distressing voice hearing.</p><p><strong>Methods: </strong>Talking with Voices-II was a rater-blinded, parallel-arm, multisite, randomised controlled trial to test the efficacy and underlying mechanisms of TwV therapy compared with treatment as usual (TAU) in community-based National Health Service mental health services across four UK sites. Participants with SMHPs who experienced distressing voices were randomly assigned (1:1), using random-sized blocks, stratified by site and presence of schizophrenia diagnosis, to receive either TwV plus TAU or TAU alone. Therapy was provided in up to 26 sessions over 8 months, and assessments were conducted at baseline, 8 months, and 14 months by assessors masked to treatment allocation. The primary outcome was the Questionnaire about the Process of Recovery score at 8 months, a self-reported measure of personal recovery in psychosis. Secondary outcomes were voice-related measures, self-beliefs, dissociation, and post-traumatic stress disorder (PTSD) symptoms. The primary analysis followed the intention-to-treat principle, and moderation and mediation were prespecified in the statistical analysis plan. The mediation analysis was carried out using the mediate command, utilising bootstrapping to obtain percentile CIs. The trial was prospectively registered with ISRCTN, ISRCTN15897915, and all research and clinical procedures were co-led by individuals with lived experience of psychosis.</p><p><strong>Findings: </strong>Between Sept 1, 2023, and June 30, 2025, we screened 1316 participants, of whom 309 consented, completed baseline assessments, and were randomly assigned to either TwV plus TAU (n=156) or TAU alone (n=153). The mean age of participants was 41·1 years (SD 13·1). 159 (52%) participants were men, 145 (47%) were women, and four (1%) were another gender, and one preferred not to say; 222 (72%) participants were White. At 8 months, personal recovery was significantly better in the TwV group than in the TAU group (adjusted difference 6·97 [95% CI 5·00-8·95]; p<0·0001; standardised effect size [SES] 0·63). Significant differences favouring TwV were found for 12 (80%) of 15 of secondary outcomes, unadjusted for multiple testing, including all voice-related measures, negative self-beliefs, and PTSD outcomes, with SES ranging from 0·18 to","PeriodicalId":48784,"journal":{"name":"Lancet Psychiatry","volume":" ","pages":""},"PeriodicalIF":21.1,"publicationDate":"2026-11-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149388367","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Lancet PsychiatryPub Date : 2026-11-10DOI: 10.1016/S2215-0366(26)00326-3
Paul C F van Haaren, Jakob M van Gaalen, Edoardo G Ostinelli, Kiyomi Shinohara, Aran Tajika, Rosario Aronica, Nobuatsu Aoki, Eduarda Batista, Suzanne A Ligthart, Christiaan H Vinkers, Orestis Efthimiou, Andrea Cipriani, Toshi A Furukawa, Henricus G Ruhé
{"title":"Comparative efficacy and acceptability of antidepressants in the long-term treatment of major depressive disorder: a systematic review and network meta-analysis.","authors":"Paul C F van Haaren, Jakob M van Gaalen, Edoardo G Ostinelli, Kiyomi Shinohara, Aran Tajika, Rosario Aronica, Nobuatsu Aoki, Eduarda Batista, Suzanne A Ligthart, Christiaan H Vinkers, Orestis Efthimiou, Andrea Cipriani, Toshi A Furukawa, Henricus G Ruhé","doi":"10.1016/S2215-0366(26)00326-3","DOIUrl":"https://doi.org/10.1016/S2215-0366(26)00326-3","url":null,"abstract":"<p><strong>Background: </strong>Major depressive disorder carries high risks of relapse and chronicity, necessitating treatments that achieve and maintain response (sustained response). This study aimed to compare antidepressants on their ability to achieve sustained response, and on acceptability, by synthesising data from randomised controlled trials.</p><p><strong>Methods: </strong>For this systematic review and network meta-analysis, we searched the Cochrane Register, AMED, CINAHL, Embase, LILACS, MEDLINE, MEDLINE In-Progress, PsycINFO, the UK National Research Register, and regulatory agency websites from inception to March 27, 2026. We included double-blind randomised controlled trials that compared any of 21 antidepressants head-to-head or with placebo for long-term treatment (>12 weeks) of adult unipolar major depressive disorder. We included enrichment, non-enrichment, continuation, and continuation-extension designs, and extracted study-level data. We could not derive the sex or gender distribution of participants other than female and did not extract data on race or ethnicity. Primary outcomes were efficacy (sustained response rate) and acceptability (all-cause discontinuation). We synthesised data in random-effects pairwise and network meta-analyses to estimate pooled odds ratios (ORs), using fluoxetine as a reference in the ranked forest plots. The primary analysis included head-to-head continuation and continuation-extension design studies. Enrichment design studies were incorporated in the analysis using a chain-of-evidence approach. Risk-of-bias assessment was done using the Cochrane Risk of Bias 2 tool. No people with lived experience were involved in the design, conduct, or interpretation of this study.</p><p><strong>Findings: </strong>From 54 231 records, 115 studies (30 428 participants; mean age 45·3 years [SD 8·5], 20 066 [66%] female) were included. In head-to-head continuation and continuation-extension design studies (35 studies; n=9888), sustained response differed across antidepressants. Escitalopram (OR 1·62, 95% CI 1·21-2·18), duloxetine (OR 1·57, 1·08-2·26), and agomelatine (OR 1·40, 1·06-1·85) showed higher sustained response rates than fluoxetine. Bupropion and reboxetine showed lower sustained response rates against four other antidepressants in the league table of pairwise comparisons. Escitalopram (OR 0·60, 0·43-0·83) and duloxetine (OR 0·64, 0·44-0·95) demonstrated lower all-cause discontinuation compared with fluoxetine, while reboxetine and milnacipran showed higher all-cause discontinuation against six and four other antidepressants, respectively, in the league table of pairwise comparisons. Sensitivity analyses incorporating enrichment-design studies corroborated these results. However, the certainty of evidence of the network meta-analysis results and the risk of bias in the included studies (19 [54%] of 35 had high risk of bias) might limit the reliability of the current findings.</p><p><strong>Interpreta","PeriodicalId":48784,"journal":{"name":"Lancet Psychiatry","volume":" ","pages":""},"PeriodicalIF":21.1,"publicationDate":"2026-11-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149388366","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Lancet PsychiatryPub Date : 2026-11-06DOI: 10.1016/S2215-0366(26)00333-0
Ömer Asan
{"title":"\"Where's Daddy?\": attachment and the language of AI-assisted weapons targeting.","authors":"Ömer Asan","doi":"10.1016/S2215-0366(26)00333-0","DOIUrl":"https://doi.org/10.1016/S2215-0366(26)00333-0","url":null,"abstract":"","PeriodicalId":48784,"journal":{"name":"Lancet Psychiatry","volume":" ","pages":""},"PeriodicalIF":21.1,"publicationDate":"2026-11-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149358188","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Lancet PsychiatryPub Date : 2026-11-01Epub Date: 2026-08-20DOI: 10.1016/S2215-0366(26)00197-5
Alejandra Barcala
{"title":"Mental health law and policy in Argentina: from rights expansion to rollback.","authors":"Alejandra Barcala","doi":"10.1016/S2215-0366(26)00197-5","DOIUrl":"10.1016/S2215-0366(26)00197-5","url":null,"abstract":"","PeriodicalId":48784,"journal":{"name":"Lancet Psychiatry","volume":" ","pages":"911-912"},"PeriodicalIF":21.1,"publicationDate":"2026-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148799972","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}